Chair and Department of Experimental and Clinical Physiology, Laboratory of Centre for Preclinical Research, Medical University of Warsaw, 1b Banacha Street, 02-097 Warsaw, Poland.
Department of Methodology, Laboratory of Centre for Preclinical Research, Medical University of Warsaw, 1b Banacha Street, 02-097 Warsaw, Poland.
Int J Mol Sci. 2024 Oct 2;25(19):10621. doi: 10.3390/ijms251910621.
Patients with unstable angina present clinical characteristics of atherosclerotic plaque vulnerability, contrary to chronic coronary syndrome patients. The process of athersclerotic plaque destabilization is also regulated by microRNA particles. In this study, the investigation on expression levels of microRNAs inhibiting the expression of proteins that protect from atherosclerotic plaque progression (miR-92a inhibiting KLF2, miR-10b inhibiting KLF4, miR-126 inhibiting MerTK, miR-98 inhibiting IL-10, miR-29b inhibiting TGFβ1) was undertaken. A number of 62 individuals were enrolled-unstable angina (UA, = 14), chronic coronary syndrome (CCS, = 38), and healthy volunteers (HV, = 10). Plasma samples were taken, and microRNAs expression levels were assessed by qRT-PCR. UA patients presented significantly increased miR-10b levels compared to CCS patients (0.097 vs. 0.058, = 0.033). Moreover, in additional analysis when UA patients were grouped together with stable patients with significant plaque in left main or proximal left anterior descending ("UA and LM/proxLAD" group, = 29 patients) and compared to CCS patients with atherosclerotic lesions in other regions of coronary circulation ("CCS other" group, = 25 patients) the expression levels of both miR-10b (0.104 vs. 0.046; = 0.0032) and miR-92a (92.64 vs. 54.74; = 0.0129) were significantly elevated. , the study revealed significantly increased expression levels of miR-10b and miR-92a, a regulator of endothelial protective KLF factors (KLF4 and KLF2, respectively) in patients with more vulnerable plaque phenotypes.
不稳定型心绞痛患者具有动脉粥样硬化斑块易损性的临床特征，与慢性冠脉综合征患者不同。动脉粥样硬化斑块不稳定性的发展过程也受到 microRNA 颗粒的调控。在本研究中，我们研究了抑制动脉粥样硬化斑块进展蛋白表达的 microRNA （miR-92a 抑制 KLF2，miR-10b 抑制 KLF4，miR-126 抑制 MerTK，miR-98 抑制 IL-10，miR-29b 抑制 TGFβ1）的表达水平。共纳入 62 名个体：不稳定型心绞痛（UA，n = 14）、慢性冠脉综合征（CCS，n = 38）和健康志愿者（HV，n = 10）。采集血浆样本，通过 qRT-PCR 评估 microRNA 表达水平。与 CCS 患者相比，UA 患者的 miR-10b 水平显著升高（0.097 比 0.058， = 0.033）。此外，进一步分析当 UA 患者与左主干或左前降支有明显斑块的稳定型患者（“UA 和 LM/proxLAD”组，n = 29 例）和与其他冠状动脉循环区域有动脉粥样硬化病变的 CCS 患者（“CCS 其他”组，n = 25 例）放在一起比较时，miR-10b（0.104 比 0.046； = 0.0032）和 miR-92a（92.64 比 54.74； = 0.0129）的表达水平均显著升高。综上所述，本研究表明，在具有更易损斑块表型的患者中，miR-10b 和 miR-92a 的表达水平显著升高，miR-10b 和 miR-92a 是内皮保护 KLF 因子（分别为 KLF4 和 KLF2）的调节剂。
